Evan Yu
Evan Yu
Unknown affiliation
Verified email at
Cited by
Cited by
Abiraterone in metastatic prostate cancer without previous chemotherapy
CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ...
New England Journal of Medicine 368 (2), 138-148, 2013
Early childhood development coming of age: science through the life course
MM Black, SP Walker, LCH Fernald, CT Andersen, AM DiGirolamo, C Lu, ...
The Lancet 389 (10064), 77-90, 2017
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ...
The Lancet 389 (10064), 67-76, 2017
Lentivirus-delivered stable gene silencing by RNAi in primary cells
SA Stewart, DM Dykxhoorn, D Palliser, H Mizuno, EY Yu, DS An, ...
Rna 9 (4), 493-501, 2003
Quantitative and stoichiometric analysis of the microRNA content of exosomes
JR Chevillet, Q Kang, IK Ruf, HA Briggs, LN Vojtech, SM Hughes, ...
Proceedings of the National Academy of Sciences 111 (41), 14888-14893, 2014
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
A Kumar, I Coleman, C Morrissey, X Zhang, LD True, R Gulati, R Etzioni, ...
Nature medicine 22 (4), 369-378, 2016
Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy
JE Rosenberg, PH O’Donnell, AV Balar, BA McGregor, EI Heath, YY Evan, ...
Journal of Clinical Oncology 37 (29), 2592, 2019
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ...
The Lancet Oncology 22 (7), 931-945, 2021
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer
CJ Kuo, F Farnebo, EY Yu, R Christofferson, RA Swearingen, R Carter, ...
Proceedings of the National Academy of Sciences 98 (8), 4605-4610, 2001
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer
KN Chi, SJ Hotte, EY Yu, D Tu, BJ Eigl, I Tannock, F Saad, S North, ...
Journal of clinical oncology 28 (27), 4247-4254, 2010
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer
EY Yu, G Wilding, E Posadas, M Gross, S Culine, C Massard, MJ Morris, ...
Clinical Cancer Research 15 (23), 7421-7428, 2009
The role of lineage plasticity in prostate cancer therapy resistance
H Beltran, A Hruszkewycz, HI Scher, J Hildesheim, J Isaacs, EY Yu, ...
Clinical cancer research 25 (23), 6916-6924, 2019
Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019
VN Giri, KE Knudsen, WK Kelly, HH Cheng, KA Cooney, MS Cookson, ...
Journal of Clinical Oncology 38 (24), 2798, 2020
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer
MD Galsky, SK Pal, S Chowdhury, LC Harshman, SJ Crabb, YN Wong, ...
Cancer 121 (15), 2586-2593, 2015
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer
TK Choueiri, RW Ross, S Jacobus, U Vaishampayan, YY Evan, DI Quinn, ...
Journal of clinical oncology 30 (5), 507, 2012
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma
M Hussain, S Daignault, N Agarwal, PD Grivas, AO Siefker‐Radtke, ...
Cancer 120 (17), 2684-2693, 2014
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
MT Schweizer, K Haugk, JS McKiernan, R Gulati, HH Cheng, JL Maes, ...
PloS one 13 (6), e0198389, 2018
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis
T Koreckij, H Nguyen, LG Brown, EY Yu, RL Vessella, E Corey
British journal of cancer 101 (2), 263-268, 2009
A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy
K Zargar-Shoshtari, H Zargar, Y Lotan, JB Shah, BW Van Rhijn, ...
The Journal of Urology 195 (1), 53-59, 2016
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer …
KN Chi, EY Yu, C Jacobs, J Bazov, C Kollmannsberger, CS Higano, ...
Annals of Oncology 27 (6), 1116-1122, 2016
The system can't perform the operation now. Try again later.
Articles 1–20